83615
document
Early effects of continuous low-dosage all-norgestrel administered alone or with estrogen . Twenty-six postmenopausal women participated in a double-blind trial involving treatment according to a Latin square design with either ( i ) dl-norgestrel alone ( 0.075 mg/day ) continuously for two cycles , ( ii ) estradiol-17 beta alone ( 1 mg on 25 of 28 days ) for two cycles , or ( iii ) the combined hormones for six cycles . A placebo control cycle followed each hormonal treatment . Plasma triglycerides decreased by an average 22 % during treatment with either dl-norgestrel alone ( 123 +/- 11 vs. 160 +/- 10 mg/dl , n = 25 , P < 0.005 ) or combination therapy ( 126 +/- 11 vs. 162 +/- 11 , n = 25 , P < 0.005 ) as compared with control . Plasma total cholesterol fell by 5 % during two cycles of treatment with either dl-norgestrel alone ( 229 +/- 11 vs. 242 +/- 10 mg/dl , n = 25 , P < 0.02 ) or combination therapy ( 233 +/- 11 vs. 246 +/- 10 , n = 25 , P < 0.05 ) versus placebo . During the fifth and sixth cycles of combination therapy 94 % of cycles were free of flushing ( vs. 31 % for control , P < 0.01 ) , 64 % of cycles were free of spotting not requiring protection ( control 75 % ) , 96 % of cycles were free of vaginal bleeding ( control 100 % ) , endometrial biopsy showed inactive endometrium in nine of the 10 subjects re-biopsied , fasting blood pyruvate decreased by 20 % ( P < 0.05 ) and diastolic blood pressure fell by 4 % compared with control ( P < 0.05 ) , whereas glucose tolerance was unchanged . There was a significant reduction in vasomotor flushing beginning with the third to fourth cycles of combination therapy .
83616
Intervention_Pharmacological
all-norgestrel
83617
Intervention_Pharmacological
dl-norgestrel alone
83618
Intervention_Pharmacological
estradiol-17 beta alone
83619
Intervention_Pharmacological
combined hormones
83620
Intervention_Control
placebo control
83621
Intervention_Pharmacological
dl-norgestrel
83622
Intervention_Pharmacological
dl-norgestrel
83623
Outcome_Physical
Plasma triglycerides decreased
83624
Outcome_Physical
Plasma total cholesterol
83625
Outcome_Physical
free of flushing
83626
Outcome_Physical
free of spotting not requiring protection
83627
Outcome_Physical
free of vaginal bleeding
83628
Outcome_Physical
inactive endometrium
83629
Outcome_Physical
fasting blood pyruvate decreased
83630
Outcome_Physical
diastolic blood pressure fell
83631
Outcome_Physical
glucose tolerance was unchanged
83632
Outcome_Physical
vasomotor flushing